Change of Director's Interest Notice (x6)
Released
Released
Announcement PDF
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given
to ASX become ASX’s property and may be made public.
Introduced 30/9/2001.
Amended 01/01/11
Name of Entity:
Radiopharm Theranostics Limited (ASX: RAD)
ABN:
57 647 877 889
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of
section 205G of the Corporations Act.
Name of Director:
Leila Alland
Date of Last Notice:
15 December 2023
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a
director” should be disclosed in this part.
Direct or Indirect Interest
Direct
Nature of indirect interest
(including registered holder)
-
Date of change
13 Sep 2024
Note: Provide details of the circumstances giving rise to the
relevant interest.
No. of securities held prior to change
Direct
Indirect
Total
Class
Shares
71,740
71,740
Options
1,900,002
1,900,002
RAD
ORDINARY FULLY PAID
RADOA OPTION EXPIRING 24-AUG-2026
Number acquired
Direct
Indirect
Total
Shares
1,000,000
1,000,000
Options
500,000
500,000
Shares
Options
Number disposed
Direct
Indirect
Total
-
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 1
-
Appendix 3Y
Change of Director’s Interest Notice
Value/Consideration
Note:
If consideration is non-cash, provide details and estimated
valuation
$0.04 per RAD ordinary share
(with free attaching RADOA option per placement
announced 25 Jun 2024)
No. of securities held after change
Direct
Indirect
Total
Nature of change
Example:
on-market trade, off-market trade, exercise of options, issue of
securities under dividend reinvestment plan, participation in
buy-back
Shares
1,071,740
1,071,740
Options
2,400,002
2,400,002
Issue of placement shares and options approved by
shareholders at the General Meeting held on 14
August 2024.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a
director” should be disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
(if issued securities)
N/A
Date of change
N/A
No. and class of securities to which
interest related prior to change
N/A
Interest acquired
N/A
Interest disposed
N/A
Value/Consideration
N/A
Interest after change
N/A
Note: Details are only required for a contract in
relation to which the interest has changed
Note: If consideration is non-cash, provide details
and an estimated valuation
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Appendix 3Y
Change of Director’s Interest Notice
Part 3 – Closed period
Were the interests in the securities or
contracts detailed above traded
during a +closed period where prior
written clearance was required?
No
If so, was prior written clearance
provided to allow the trade to proceed
during this period?
N/A
If prior written clearance was
provided, on what date was this
provided?
N/A
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 3
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given
to ASX become ASX’s property and may be made public.
Introduced 30/9/2001.
Amended 01/01/11
Name of Entity:
Radiopharm Theranostics Limited (ASX: RAD)
ABN:
57 647 877 889
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of
section 205G of the Corporations Act.
Name of Director:
Riccardo Canevari
Date of Last Notice:
15 December 2023
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a
director” should be disclosed in this part.
Direct or Indirect Interest
Direct and Indirect
Nature of indirect interest
(including registered holder)
Indirect interest held via broker nominee account
Date of change
13 Sep 2024
No. of securities held prior to change
Shares
Options
Direct
8,503,584
29,824,013
Indirect
1,150,000
Total
9,653,584
29,824,013
RAD
ORDINARY FULLY PAID
RADOA OPTION EXPIRING 24-AUG-2026
RADAN OPTION EXPIRING VARIOUS
DATES EX VARIOUS PRICES
Shares
Options
Direct
(a) 3,750,000
(a) 1,875,000
(b) 24,000,000
Indirect
Total
3,750,000
25,875,000
Shares
Options
Direct
Indirect
Total
-
Note: Provide details of the circumstances giving rise to the
relevant interest.
Class
Number acquired
Number disposed
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 1
Appendix 3Y
Change of Director’s Interest Notice
Value/Consideration
Note:
If consideration is non-cash, provide details and estimated
valuation
No. of securities held after change
(a) $0.04 per RAD ordinary share
(with free attaching RADOA option per
placement announced 25 Jun 2024)
(b) Incentive options approved by shareholders at
General Meeting held 14 August 2024
Direct
Indirect
Total
Nature of change
Example:
on-market trade, off-market trade, exercise of options, issue of
securities under dividend reinvestment plan, participation in
buy-back
Shares
12,253,584
1,150,000
13,403,584
Options
55,699,013
55,699,013
(a) Issue of placement shares and options
approved by shareholders at the General
Meeting held 14 August 2024.
(b) Issue of incentive options approved by
shareholders at General Meeting held 14
August 2024.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a
director” should be disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
(if issued securities)
N/A
Date of change
N/A
No. and class of securities to which
interest related prior to change
N/A
Interest acquired
N/A
Interest disposed
N/A
Value/Consideration
N/A
Interest after change
N/A
Note: Details are only required for a contract in
relation to which the interest has changed
Note: If consideration is non-cash, provide details
and an estimated valuation
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Appendix 3Y
Change of Director’s Interest Notice
Part 3 – Closed period
Were the interests in the securities or
contracts detailed above traded
during a +closed period where prior
written clearance was required?
No
If so, was prior written clearance
provided to allow the trade to proceed
during this period?
N/A
If prior written clearance was
provided, on what date was this
provided?
N/A
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 3
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity
Radiopharm Theranostics Limited (ASX: RAD)
ABN
57 647 877 889
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
Name of Director
Phillip Hains
Date of last notice
26 March 2024
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Direct or indirect interest
Direct and Indirect
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Director related entities:
The CFO Solution Team Pty Ltd
Shared Office Services Pty Ltd
Date of change
13 Sep 2024
No. of securities held prior to change
Shares
Options
Direct
1,900,002
Indirect
6,256,632
2,083,560
Total
6,256,632
3,983,562
RAD
ORDINARY FULLY PAID
RADOA OPTION EXPIRING 24-AUG-2026
Shares
Options
Direct
Indirect
9,700,000
4,850,000
Total
9,700,000
4,850,000
Shares
Options
Direct
Indirect
Total
$0.04 per RAD ordinary share
(with free attaching RADOA option per
placement announced 25 Jun 2024)
Class
Number acquired
Number disposed
Value/Consideration
Note: If consideration is non-cash, provide details and estimated valuation
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 1
Appendix 3Y
Change of Director’s Interest Notice
No. of securities held after change
Nature of change
Example: on-market trade, off-market trade, exercise of options, issue of
securities under dividend reinvestment plan, participation in buy-back
Shares
Options
Direct
1,900,002
Indirect
15,956,632
6,933,560
Total
15,956,632
8,833,562
Issue of placement shares and options approved
by shareholders at the General Meeting held on
14 August 2024.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
N/A
(if issued securities)
Date of change
N/A
No. and class of securities to which N/A
interest related prior to change
Note: Details are only required for a contract in relation
to which the interest has changed
Interest acquired
N/A
Interest disposed
N/A
Value/Consideration
N/A
Note: If consideration is non-cash, provide details and an
estimated valuation
Interest after change
N/A
Part 3 – +Closed period
Were the interests in the securities or contracts detailed above No
traded during a +closed period where prior written clearance
was required?
If so, was prior written clearance provided to allow the trade to N/A
proceed during this period?
If prior written clearance was provided, on what date was this N/A
provided?
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given
to ASX become ASX’s property and may be made public.
Introduced 30/9/2001.
Amended 01/01/11
Name of Entity:
Radiopharm Theranostics Limited (ASX: RAD)
ABN:
57 647 877 889
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of
section 205G of the Corporations Act.
Name of Director:
Paul Hopper
Date of Last Notice:
7 December 2023
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a
director” should be disclosed in this part.
Direct or Indirect Interest
Direct and Indirect
Nature of indirect interest
(including registered holder)
Director related entity
Date of change
13 September 2024
Note: Provide details of the circumstances giving rise to the
relevant interest.
No. of securities held prior to change
Direct
Indirect
Total
Class
Number acquired
Shares
400,000
93,821,428
94,221,428
Options
9,017,518
9,017,518
RAD ordinary shares
RADOA listed options
Direct
Indirect
Total
Number disposed
Direct
Indirect
Total
Shares
55,000,000
55,000,000
Options
27,500,000
27,500,000
Shares
Options
-
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 1
-
Appendix 3Y
Change of Director’s Interest Notice
Value/Consideration
Note:
If consideration is non-cash, provide details and estimated
valuation
$0.04 per RAD ordinary share
(with free attaching RADOA listed option per
placement announced 25 Jun 2024)
No. of securities held after change
Direct
Indirect
Total
Nature of change
Example:
on-market trade, off-market trade, exercise of options, issue of
securities under dividend reinvestment plan, participation in
buy-back
Shares
55,400,000
93,821,428
149,221,428
Options
27,500,000
9,017,518
36,517,518
Issue of placement shares and options
approved by shareholders at the General
Meeting held on 14 August 2024.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a
director” should be disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
(if issued securities)
N/A
Date of change
N/A
No. and class of securities to which
interest related prior to change
N/A
Interest acquired
N/A
Interest disposed
N/A
Value/Consideration
N/A
Interest after change
N/A
Note: Details are only required for a contract in
relation to which the interest has changed
Note: If consideration is non-cash, provide details
and an estimated valuation
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Appendix 3Y
Change of Director’s Interest Notice
Part 3 – Closed period
Were the interests in the securities or
contracts detailed above traded
during a +closed period where prior
written clearance was required?
No
If so, was prior written clearance
provided to allow the trade to proceed
during this period?
N/A
If prior written clearance was
provided, on what date was this
provided?
N/A
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 3
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given
to ASX become ASX’s property and may be made public.
Introduced 30/9/2001.
Amended 01/01/11
Name of Entity:
Radiopharm Theranostics Limited (ASX: RAD)
ABN:
57 647 877 889
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of
section 205G of the Corporations Act.
Name of Director:
Hester Larkin
Date of Last Notice:
15 December 2023
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a
director” should be disclosed in this part.
Direct or Indirect Interest
Direct and indirect
Nature of indirect interest
(including registered holder)
Held via broker nominee account
Date of change
8 December 2023
Note: Provide details of the circumstances giving rise to the
relevant interest.
No. of securities held prior to change
Direct
Indirect
Total
Class
Number acquired
Shares
94,247
94,247
Options
1,900,002
1,900,002
RAD
ORDINARY FULLY PAID
RADOA OPTION EXPIRING 24-AUG-2026
Direct
Indirect
Total
Number disposed
Direct
Indirect
Total
Shares
550,000
550,000
Options
275,000
275,000
Shares
Options
-
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 1
-
Appendix 3Y
Change of Director’s Interest Notice
Value/Consideration
Note:
If consideration is non-cash, provide details and estimated
valuation
$0.04 per RAD ordinary share
(with free attaching RADOA option per placement
announced 25 Jun 2024)
No. of securities held after change
Direct
Indirect
Total
Nature of change
Example:
on-market trade, off-market trade, exercise of options, issue of
securities under dividend reinvestment plan, participation in
buy-back
Shares
550,000
94,247
644,247
Options
2,175,002
2,175,002
Issue of placement shares and options approved by
shareholders at the General Meeting held on 14
August 2024.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a
director” should be disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
(if issued securities)
N/A
Date of change
N/A
No. and class of securities to which
interest related prior to change
N/A
Interest acquired
N/A
Interest disposed
N/A
Value/Consideration
N/A
Interest after change
N/A
Note: Details are only required for a contract in
relation to which the interest has changed
Note: If consideration is non-cash, provide details
and an estimated valuation
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Appendix 3Y
Change of Director’s Interest Notice
Part 3 – Closed period
Were the interests in the securities or
contracts detailed above traded
during a +closed period where prior
written clearance was required?
No
If so, was prior written clearance
provided to allow the trade to proceed
during this period?
N/A
If prior written clearance was
provided, on what date was this
provided?
N/A
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 3
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given
to ASX become ASX’s property and may be made public.
Introduced 30/9/2001.
Amended 01/01/11
Name of Entity:
Radiopharm Theranostics Limited (ASX: RAD)
ABN:
57 647 877 889
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of
section 205G of the Corporations Act.
Name of Director:
Ian Turner
Date of Last Notice:
15 December 2023
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a
director” should be disclosed in this part.
Direct or Indirect Interest
Direct and indirect
Nature of indirect interest
(including registered holder)
Superannuation fund
Date of change
13 September 2024
Note: Provide details of the circumstances giving rise to the
relevant interest.
No. of securities held prior to change
Direct
Indirect
Total
Class
Number acquired
Shares
280,595
590,833
871,428
Options
5,002,524
70,422
5,072,946
RAD
ORDINARY FULLY PAID
RADOA OPTION EXPIRING 24-AUG-2026
Direct
Indirect
Total
Number disposed
Direct
Indirect
Total
Shares
2,250,000
1,500,000
3,750,000
Options
1,125,000
750,000
1,875,000
Shares
Options
-
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 1
-
Appendix 3Y
Change of Director’s Interest Notice
Value/Consideration
Note:
If consideration is non-cash, provide details and estimated
valuation
$0.04 per RAD ordinary share
(with free attaching RADOA option per placement
announced 25 Jun 2024)
No. of securities held after change
Direct
Indirect
Total
Nature of change
Example:
on-market trade, off-market trade, exercise of options, issue of
securities under dividend reinvestment plan, participation in
buy-back
Shares
2,530,595
2,090,833
4,621,428
Options
6,127,524
820,422
6,947,946
Issue of placement shares and options approved by
shareholders at the General Meeting held on 14
August 2024.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a
director” should be disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
(if issued securities)
N/A
Date of change
N/A
No. and class of securities to which
interest related prior to change
N/A
Interest acquired
N/A
Interest disposed
N/A
Value/Consideration
N/A
Interest after change
N/A
Note: Details are only required for a contract in
relation to which the interest has changed
Note: If consideration is non-cash, provide details
and an estimated valuation
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Appendix 3Y
Change of Director’s Interest Notice
Part 3 – Closed period
Were the interests in the securities or
contracts detailed above traded
during a +closed period where prior
written clearance was required?
No
If so, was prior written clearance
provided to allow the trade to proceed
during this period?
N/A
If prior written clearance was
provided, on what date was this
provided?
N/A
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 3
Share your feedback
Discover